Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Current Liabilities (2016 - 2026)

Lexaria Bioscience's Total Current Liabilities history spans 12 years, with the latest figure at $214671.0 for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 88.22% to $214671.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $214671.0, a 88.22% decrease, with the full-year FY2025 number at $1.5 million, up 35.84% from a year prior.
  • Total Current Liabilities hit $214671.0 in Q1 2026 for Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for LEXX hit a ceiling of $1.8 million in Q1 2025 and a floor of $81717.0 in Q1 2024.
  • Historically, Total Current Liabilities has averaged $625259.7 across 5 years, with a median of $267735.0 in 2023.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 2130.16% in 2025 and later plummeted 88.22% in 2026.
  • Tracing LEXX's Total Current Liabilities over 5 years: stood at $281520.0 in 2022, then crashed by 55.77% to $124523.0 in 2023, then surged by 139.15% to $297798.0 in 2024, then skyrocketed by 389.1% to $1.5 million in 2025, then plummeted by 85.26% to $214671.0 in 2026.
  • Business Quant data shows Total Current Liabilities for LEXX at $214671.0 in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.